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Abstract: The pathophysiology of preeclampsia (PE) is poorly understood; however, there is a large
body of evidence that suggests a role of immune cells in the development of PE. Amongst these,
B cells are a dominant element in the pathogenesis of PE, and they have been shown to play an
important role in various immune-mediated diseases, both as pro-inflammatory and regulatory cells.
Perinatal cells are defined as cells from birth-associated tissues isolated from term placentas and fetal
annexes and more specifically from the amniotic membrane, chorionic membrane, chorionic villi,
umbilical cord (including Wharton’s jelly), the basal plate, and the amniotic fluid. They have drawn
particular attention in recent years due to their ability to modulate several aspects of immunity,
making them promising candidates for the prevention and treatment of various immune-mediated
diseases. In this review we describe main findings regarding the multifaceted in vitro and in vivo
immunomodulatory properties of perinatal cells, with a focus on B lymphocytes. Indeed, we discuss
evidence on the ability of perinatal cells to inhibit B cell proliferation, impair B cell differentiation, and
promote regulatory B cell formation. Therefore, the findings discussed herein unveil the possibility
to modulate B cell activation and function by exploiting perinatal immunomodulatory properties,
thus possibly representing a novel therapeutic strategy in PE.
Keywords: perinatal cells; preeclampsia; B cells; placenta; amnion; umbilical cord; autoantibodies
1. Introduction
Preeclampsia (PE) is a hypertensive disorder during pregnancy that affects 2% to 8%
of all pregnant women and is one of the main causes of maternal and fetal morbidity and
mortality worldwide [1,2]. The pathophysiology of PE is poorly understood; however,
several lines of evidence support a role of the immune system in the development of PE.
Among immune cells, B cells represent a dominant component in the pathogenesis of PE.
Therefore, studies aimed to dissect the different B cell subsets and their number alterations
could be of great importance in understanding the pathophysiology of PE. On the other
hand, mechanisms that affect B cells and their activation status may represent a valid
therapeutic approach in PE.
Perinatal cells are defined as cells from birth-associated tissues isolated from term
placentas and fetal annexes and more specifically from the amniotic membrane, chorionic
membrane, chorionic villi, umbilical cord (including Wharton’s jelly), the basal plate, and
the amniotic fluid [3]. They constitute a promising tool as a therapeutic approach in
PE, especially in the light of the recent identification of B cells as target of the immune
modulatory action of perinatal cells.
Int. J. Mol. Sci. 2021, 22, 3405. https://doi.org/10.3390/ijms22073405 https://www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2021, 22, 3405 2 of 18
In this review we summarize (i) the pathophysiology of PE, (ii) the role of immune
cells in PE, (iii) with a focus on the role of B cells in PE. Moreover, we discuss the current
knowledge about the (iv) in vitro and (v) in vivo effects of perinatal cells on B cells and
(vi) how these effects could contribute to the development of a PE treatment.
2. Preeclampsia: Pathogenic Mechanisms
2.1. Definition and Pathogenesis
PE is defined by the presence of hypertension accompanied by proteinuria after
20 weeks of gestation or [1,2], in the absence of proteinuria, hypertension accompanied by
the presence of severe features such as thrombocytopenia, renal insufficiency, impaired liver
function, pulmonary edema, neurological signs, and fetal growth restriction [1,2,4]. The
pathophysiology of PE is poorly understood, and the underlying mechanisms contributing
to PE are an active area of research. What is clear is that PE is a placental disease, as
the clinical syndrome does not develop in the absence of placenta, and delivery is the
definitive treatment.
PE begins with abnormal placentation in the first trimester and is characterized by
impaired trophoblast invasion and incomplete spiral artery remodeling, followed by an
uteroplacental ischemia that drives the hypertensive, multi-organ failure response detected
in the maternal preeclamptic syndrome [5]. The early phases of a normal implantation
are characterized by a low oxygen tension environment, and this condition favors the
proliferation of trophoblasts, which anchor the blastocyst to maternal decidua with spiral
arteries. Subsequently, intervillous spaces allow the arrival of maternal blood, which
increases oxygen tension and promotes the trophoblast differentiation from a proliferative
to an invasive phenotype, with invasion and remodeling of spiral arteries.
2.2. Hypoxia and Oxidative Stress
Women with PE have upregulation of placental hypoxia-inducible factor (HIF), a
marker of cellular oxygen deprivation, and hypoxia-related gene signatures, strongly sug-
gesting a role of hypoxia in the pathogenesis of PE. Indeed, hypoxia may cause the failure
of trophoblastic differentiation from the proliferative to the invasive phenotype. Conse-
quently, poor spiral artery invasion may cause intermittent hypoxia and reoxygenation
and generate oxidative stress [6]. When compared with women with normal pregnan-
cies, women with PE display increased placental mitochondrial activity and production
of reactive oxygen species (ROS), mainly superoxide anion, and decreased expression of
superoxide dismutase and glutathione peroxidase, antioxidant enzymes involved in ROS
neutralization [7,8].
2.3. Angiogenic Factors
Hypoxia has been shown to upregulate expression and secretion of soluble fms-
like tyrosine kinase-1 (sFlt-1) protein in primary trophoblast cultures from first-trimester
placentas [9]. sFlt-1 may represent a central molecule in PE because although its serum level
increases significantly in pregnancy, there is a further increase in PE. sFlt-1 acts as a decoy
receptor sequestrating circulating vascular-endothelial growth factor (VEGF) and placental
growth factor (PlGF), thereby reducing their availability for angiogenesis. Injection of sFlt-
1 in rats induced hypertension, proteinuria, and histological changes consistent with
PE [10]. Soluble endoglin (sEng), a transforming growth factor (TGF)-β inhibitor, is
another antiangiogenic, placenta-derived protein extensively studied in PE and found to be
increased in sera of preeclamptic women. sEng is a coreceptor that binds to and decreases
the levels of TGF-β, which normally induces proliferation and migration of endothelial
cells [1]. Therefore, sFlt-1 and sEng facilitate downstream endothelial dysfunction, a
vasoconstrictive state, microemboli, and placental ischemia and are positively correlated
with severity of disease [11,12].
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2.4. Heme Oxygenase, Hydrogen Sulfide, and Nitric Oxide Pathways
Moreover, a proximal pathway of Flt-1 induction involves the heme oxygenase (HO)
enzyme, whose inhibition resulted in defective trophoblast invasion in vitro [13]. The HO
enzyme degrades heme and leads to the formation of carbon monoxide (CO), which acts
as a vasodilator and reduces perfusion pressure in the placenta [14]. Expression of the HO
enzyme is reduced in PE [15], therefore potentially contributing to the pathogenesis of PE.
On the other hand, adenoviral overexpression of HO enzyme (HO-1) in endothelial cells
from preeclamptic villous explants inhibits sFlt-1 and sEng release, providing evidence
for a protective role of HO-1 in pregnancy [16]. Similarly, to CO, hydrogen sulfide (H2S)
and nitric oxide (NO) molecules have been described in the pathogenesis of PE. They
have vasodilatory and angiogenic properties and have been shown to be decreased in
PE [16,17]. Moreover, H2S modulates the levels of sFlt-1 and sEng through a VEGF-
dependent mechanism [18].
3. Role of Immune Cells in Preeclampsia
3.1. Immune Cells in Physiological Pregnancy
In addition to the above-described mechanisms, there are several lines of evidence
supporting a role of the immune system in the development of PE [19,20]. During normal
pregnancy, soon after implantation, the maternal–fetal interface contains an intensified
immune infiltrate, such as natural killer (NK) cells (~70% of total decidua lymphocytes),
followed by macrophages (~20%), T cells (~10–20%), and rare dendritic and B cells [21–23].
NK cells and macrophages play a fundamental role in this pro-inflammatory stage of
pregnancy by producing chemokines and growth factors involved in blastocyst implanta-
tion, trophoblast invasion, neo-angiogenesis, and spiral artery remodeling. Subsequently,
during the second trimester of pregnancy, a shift pivotal to fetal growth occurs whereby
the balance moves from pro-inflammatory to anti-inflammatory milieu characterized by
the presence of a T helper (Th)-2 response and macrophages with a M2-like profile [24].
These macrophages phagocytize dying cells during trophoblast invasion and placental
growth, thus preventing the release of potentially immunogenic paternal antigens. They
also interact with NK cells and induce the generation of regulatory T cells (Tregs). Tregs are
key players in maintaining fetal–maternal tolerance, in fostering an anti-inflammatory en-
vironment [25,26], and in promoting fetal survival by avoiding the recognition of paternal
semi-allogeneic tissues by the maternal immune system [26].
3.2. Immune Cells in PE
Disturbance of fetal–maternal tolerance and alteration in immune homeostasis is
widely considered to be a dominant component in the pathogenesis of PE [27]. In fact,
pregnant mice genetically deficient in NK cells display several PE-like features, such
as endothelial cell damage, alteration in placental growth, and necrosis of decidua [28].
Moreover, pregnant women at high risk of developing PE possess decidual NK with
impaired ability to chemoattract trophoblasT cells and to induce trophoblast outgrowth
from placental villous explants, leading to partial spiral artery transformation and poor
placentation [29]. Additionally, the numbers of monocytes and macrophages are altered in
preeclampsia [30,31], and a decreased number of classical monocytes is observed in women
with PE, accompanied by an increased number of intermediate monocytes [32] or non-
classical monocytes [33]. An exaggerated immune activation is another important feature
described in PE, and activation of monocytes during PE could be induced by different
factors, among which are the increased level of pro-inflammatory cytokines, such as TNFα,
IL-1β, IL-18, and the decreased level of the anti-inflammatory cytokine IL-10 [34]. Different
from normal pregnancies, women with PE present an increased number of M1 macrophages.
These M1 activated macrophages may produce pro-inflammatory cytokines and affect
spiral arteries remodeling, influencing placental blood circulation [34]. In addition, PE is
characterized by a pro-inflammatory state with an imbalance of Th1 and Th2 cells and
cytokines, in favor of a Th1 predominance. Indeed, a heightened level of pro-inflammatory
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cytokines has been detected in plasma [35,36] and placenta [37] of women with PE, as well
as an altered cytokine production by monocytes, NK cells, and lymphocytes compared
with normal pregnant women [38,39]. Increase of Th17 subpopulation has been described
in PE, with a significant correlation between PE development and Th17-, IL-2-, and IFN-
γ-producing T cells [40,41]. Moreover, upregulation of Th17 immunity decreased Treg
immunity [42], and several reports indicated low amount and functionality of specific
subsets of Treg cells in PE both at the systemic [41,43–45] and the local level, within the
decidual tissue [45,46]. In addition, decidual IL-17 positive cells are intimately involved in
neutrophil infiltration [47], and in fact, neutrophils progressively increase in pregnancy
both in the maternal systemic circulation and within the decidua, and these numbers are
even higher in PE [48,49]. In normal pregnancy, neutrophils induce protective immunity
against extracellular microbes in the uterus, but an excess of activated neutrophils, as found
in PE, may enhance the release of typical inflammatory mediators in PE, such as ROS, TNF-
α, and myeloperoxidase (MPO), causing hypertension and endothelial dysfunction [50–52].
4. Focus on B cells
4.1. B cell Main Features
Besides the immunological mediators described above, B cells also constitute a domi-
nant element in the pathogenesis of PE [53] (Figure 1).
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Figure 1. B cells and pregnancy. During physiological pregnancy B cells contribute to establish a tolerant environment.
B2 cells generate asymmetric antibodies that bind paternal antigens but do not produce responses against them, protecting
the fetus against a potential induction of the maternal lymphocyte response against paternal antigens. Moreover, regulatory
B cells are found to be enhanced in healthy pregnancies, and they contribute to establishing a tolerant environment through
the production of the anti-inflammatory IL-10. On the other hand, besides protective antibodies, the production of auto-
antibodies (such as AT1-AA, antibodies against protein C and protein S) can be detrimental for pregnancy and characterize
PE. A few indications suggest a role for B-1a cells in the production of these autoantibodies. A significant decrease in the
frequency of B-1a cells has been reported in the peripheral blood of healthy pregnant women, while it has been reported
to be elevated in patients with PE. Additionally, the percentage of memory B cells and plasma cell precursors increases
in preeclamptic women. PE, preeclampsia; Bregs, regulatory B cells; IL-10, interleukin 10; ASC, antibody-secreting cells;
AT1-AA, angiotensin receptor 1-autoantibodies. Created with BioRender.com (accessed on 21 February 2021).
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B cells are key components of the adaptive immune response and operate by producing
antibodies as well as by regulating innate immunity by acting as antigen-presenting cells
and producing cytokines.
Two major B cell populations have been described—namely, B1 and B2 cells. B1 cells
derive during fetal and perinatal life from a precursor present in the fetal liver [54,55].
B1 cells are conventionally divided into B-1a and B-1B cells according to the expression
of CD5 present on B-1a but not B-1B cells. In humans, in addition to CD5, the expression
of CD27 and CD43 was recognized as being necessary for identifying B-1a cells [56]. In
humans, B1 cells are primarily located in the peripheral blood, whereas in the murine
system B1 cells mainly populate pleural and peritoneal spaces [57]. B-1B cells provide
long-lasting immunity, producing adaptive antibodies upon antigen stimulation, whereas
B-1a cells, in the absence of antigenic stimuli, produce natural antibodies, in particular IgM,
which responds against a broad spectrum of infections [58].
Different from B1 cells, B2 cells originate in postnatal life and are produced from a
committed pluripotent hematopoietic precursor (pro-B cell) present in the bone marrow
(BM). Downstream, naïve B cells exit the BM and migrate to the follicles or the marginal
zone of spleen for further maturation and differentiation into plasma and memory B cells.
Follicular B cells and marginal zone B cells (MZ B cells) constitute the B2 cell population.
Similar to B-1b and B-1a cells, the antigen exposure and signals from T helper cells activate
and induce Igs class switching and B cell differentiation to follicular B cells, instead a
T cell-independent activation, such as that mediated by Toll-like receptor stimulation, leads
to the maturation and differentiation of MZ B cells [59–61].
4.2. B cells in Physiological Pregnancy
During pregnancy B cells are careful coordinators of an immune response critical
to the maintenance of feto–maternal tolerance. At first, they generate antibodies protect-
ing the fetus against a potential induction of the maternal lymphocyte response against
paternal antigens. Indeed, it was shown that maternal serum completely prevented the
cytotoxic effect of maternal lymphocytes on cultured trophoblast, and the immunoglobulin
IgG fraction was the major component responsible for this antigen-masking protective
effect [62,63]. Some of these antigen-specific IgGs, called asymmetric antibodies, bind to
paternal antigens with relative high affinity but lack the capacity to form antigen–antibody
complexes and are incapable of activating immune effector functions, such as fix com-
plement, phagocytosis, and cytotoxicity, thus allowing fetal survival [64]. Although not
clearly established, different studies suggest that B2 cells might be the prime B cell subset
responsible for the production of the pregnancy-protective asymmetric antibodies [65,66].
Moreover, regulatory B cells, a subtype of B cells with regulatory function, are found to
be enhanced in the first trimester of healthy pregnancies, and therefore may contribute
to establishing a tolerant environment in pregnancy by suppressing pro-inflammatory
responses through the production of the anti-inflammatory IL-10 [67].
4.3. B cells in PE
On the other hand, features of PE as an autoimmune condition are slowly being
unveiled, and in this context B cells could participate in its pathogenesis by producing
autoantibodies [53]. Indeed, in 1999, circulating autoantibodies to angiotensin receptor 1
(AT1) were reported in the sera of preeclamptic women [68]. AT1-autoantibodies (AT1-AA)
are produced in response to placental ischemia and systemic inflammation [69] and mimic
the natural ligand of the angiotensin type I receptor, highly expressed in the placenta,
that harbors vasoconstrictive activity through the production of antiangiogenic factors
s-Flt1 and endoglin [70], both hallmarks of the onset of the disease, as discussed above.
Preclinical studies strongly confirmed the role of AT1-AA in the development of PE. In-
deed, injection of AT1-AA isolated from preeclamptic women into pregnant mice induced
hypertension, proteinuria, glomerular endotheliosis, placental abnormalities, and small
fetus size, and these features were prevented by co-injection with an AT1 receptor antago-
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nist [71]. Moreover, AT1-AA caused vasoconstriction in pregnant rats [72], increased lactate
dehydrogenase release and caspase-3 and -8 activities in vitro in human umbilical cord
vein endothelial cells [73], reduced immortalized human trophoblasT cells invasion [74],
and increased production of ROS in in vitro culture models of human vascular smooth
muscle cells and trophoblasT cells [75].
Besides AT1-AA, other autoantibodies were identified in PE patients and are sus-
pected to account for the disease symptoms, such as antibodies against protein C and
protein S or the thyroid autoantibodies [76,77]. Although the impact of autoantibodies in
the development of PE has been very well described, the identification of a B cell subset
responsible for their production has been reported only recently [78–80]. A few indications
suggest a role for B-1a cells in the production of these autoantibodies. In fact, the frequency
of CD19+CD5+ B-1a cells was reported to significantly decrease in the peripheral blood
of healthy pregnant women during the third trimester [81,82], while it remained high in
patients with PE [82,83]. Of note, the frequency of the total CD19+ B cells remains relatively
constant in normal and in PE pregnancies [82]. Interestingly, Jensen et al. have demon-
strated that lymphocytes of healthy pregnant women cultured in vitro in the presence of
serum from PE patients greatly increased the percentage of CD19+CD5+ cells, very likely
due to the high human chorionic gonadotropin levels present in the supernatant of serum
and placenta of preeclamptic patients [82]. Moreover, CD19+CD5+ but not CD19+CD5−
cells isolated from peripheral blood of nonpregnant donors produce autoantibodies against
AT1-receptor when cultured with serum from PE patients. In addition, in PE patients,
CD19+CD5+ cells were detected in placental tissue, further reinforcing the idea of a role of
B-1a cells and their polyreactive antibodies in the onset of PE [82].
Other changes of human circulating B cells that may contribute to the etiology of PE
have been described. For example, the percentage of memory (CD27+CD38−) B cells and
plasma cell precursors (CD27+CD38+) increased in preeclamptic women compared with
the controls, and the percentages of plasma cells generated upon in vitro stimulation were
significantly higher in the preeclamptic group than in the control group [84].
Given these premises, strategies affecting B cells and their activation status may
represent a valid therapeutic approach in PE. Perinatal derivatives constitute a promising
tool in this context, especially in the light of the recent identification of B cells as a target of
their immune modulatory action [85,86]. The next paragraphs outline the state of the art of
the crosstalk between perinatal derivatives and B cells and the potential for this interaction
to be translated into a valid therapeutic option for PE.
5. B cells as Target of Perinatal Cells
5.1. In Vitro
Cells isolated from perinatal tissues have drawn particular attention in recent years
due to their ability to modulate several aspects of immunity, making them promising
candidates for the prevention and treatment of various immune-mediated diseases [3].
As a matter of fact, numerous in vitro studies have widely demonstrated thaT cells from
different perinatal tissues are able to interfere with the activation and the differentiation of
cells belonging to both the innate and adaptive immune system, including macrophages,
dendritic cells, natural killer cells, and T lymphocytes [87]. Although barely any knowledge
is available regarding the effect of perinatal cells on B lymphocytes, some of the complex
interactions between perinatal cells and B cells have been reported (Figure 2 and Table 1).
The majority of the studies addressing the regulation of perinatal cells on B lymphocytes
is limited to the description of a strong anti-proliferative capacity of perinatal cells on
B cells, frequently associated with bioactive factors secreted by these cells rather than a
direcT cell–cell contact. For example, Che and colleagues co-cultured human mesenchy-
mal stromal cells isolated from umbilical cord (hUC-MSC) with purified mouse splenic
B cells and demonstrated, in a contact-independent setting, that hUC-MSC were able to
abrogate the proliferation of activated B cells [88]. Similar observations were reported
when human umbilical cord matrix cells were co-cultured with a B cell cancer line, the
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Burkitt’s lymphoma cell line [89], or with autoreactive B lymphocytes from peripheral
blood mononuclear cells (PBMC) of immune thrombocytopenic patients [90].
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These studies were supported by our group using other perinatal cells such as mes-
enchymal stromal cells (MSC) isolated from the amniotic membrane (hAMSC). Specifically,
CD19+ B cell proliferation was suppressed in peripheral blood mononuclear cells (PBMC)
co-cultured with conditioned medium obtained from the in vitro culture of hAMSC (CM-
hAMSC), again underlining thaT cell-to-cell contact was not required. Similar results
were obtained with B cells purified from peripheral blood, suggesting that hAMSC and
their conditioned medium (CM) drive a direct inhibition on B cell proliferation with-
out the involvement of other intermediary immune populations [85]. Human amniotic
fluid stromal cells and their CM were also able to strongly inhibit B cell activation and
proliferation, whereby they decreased the percentage of B cells in S phase cycle and signifi-
cantly downregulated the expression of CD80/CD86 costimulatory molecules on activated
B lymphocytes [91].
However, there are contrasting data on the inhibitory effect of perinatal cells on
B cells. For example, human amniotic fluid stromal cells have been shown to inhibit
the apoptosis of B lymphocytes, thus increasing activated B cell survival. In addition,
human amniotic fluid stromal cells decreased the expression of the negative co-inhibitory
molecules B7 homolog 4 (B7H4) and programmed death-ligand 1 (PD-L1) on activated
B lymphocytes, molecules known to be involved in the negative control of inflammatory
T cell (and possibly of B cell) responses [91]. Morandi and colleagues described an increase
in B cell proliferation and a diminished spontaneous apoptosis in the presence of human
amniotic epithelial cells (hAEC) [92]. Moreover, MSC isolated from umbilical cord were
described to not affect or [93] dramatically support the in vitro growth of peripheral blood
B cells, even in the absence of cell–cell contact [94].
As previously mentioned, B cell repertoire can be conventionally divided into two
major populations, B1 and B2 cells [95,96], based on their phenotype, anatomic localization,
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self-renewing capacity, and production of natural antibodies. Interestingly, it was reported
that perinatal cells can specifically impact the B1 cell subgroup (evaluated as CD20+CD5+)
and in particular that human amniotic fluid stromal cells are able to downregulate the
proportion of B1 cells [91], thus limiting the formation of the B cell subset mainly involved
in the production of autoantibodies in PE.
CD19+ B cells can be further classified based on the differential expression of CD27 and
CD38. Indeed, these two proteins are highly upregulated at late differentiation stages, there-
fore allowing the stratification of B cells into naïve/mature B cells (CD19+CD27−CD38−),
memory B cells (CD19+CD27+CD38−), and antibody-secreting cells (ASC) or pre-plasma
cells (CD19+CD27+CD38+). Within ASC, two subsets can be discriminated based on their ex-
pression of the proteoglycan CD138: plasmablasts (CD138-) and plasma cells (CD138+) [97].
ASC/pre-plasma cells CD27+CD38+ were found to be increased in PE women [84]. Dif-
ferent studies showed that the immunomodulatory capacity of perinatal cells and of their
conditioned medium is linked to a blockage of ASC/pre-plasma cells CD27+CD38+ and
linked also to the terminal differentiation of B cells into CD138+ plasma cells, consequently
leading to a reduction in immunoglobulin secretion [85,88,91].
Contrasting results are reported for the activity of perinatal cells on memory B cells,
another B cell subtype increased in PE [84]. Co-culture of purified B cells with hu-
man amniotic fluid stromal cells has been shown to be able to reduce the proportion
of CD19+CD20+CD27+ memory B cells [91], while PBMC cultured in the presence of CM-
hAMSC was shown to increase CD19+CD27+CD38− memory B cells [85]. Although B cells
may directly interact with perinatal cells, with a consequent alteration of their proper-
ties/function, the presence of other immune cells (such as in systems using PBMC instead
purified B cells) may influence in a coordinated action the immune regulatory behavior
of perinatal cells. In addition, different stimulation used to activate B cells and the lack of
uniformity in the use of markers to characterize the B cell population could account for the
distinct results observed in different experimental setups.
The generation of plasma cells relies on the repression of paired box 5 (PAX-5) and
B cell CLL/lymphoma 6 (BCL-6) expression, keepers of B cell phenotypes [98], as well as on
the strong expression of interferon regulatory factor 4 (IRF-4), PR/SET domain 1 (PRDM1,
the gene encoding for the transcription factor B lymphocyte induced maturation protein-1,
BLIMP-1), and X-box binding protein 1 (XBP-1), identified as hallmarks of differentiation
to plasma cells [99,100]. To dissect the mechanisms through which perinatal cells could
affect B cell maturation, recent observations on the effects of hAMSC and hUC-MSC
on the expression of master regulators of CD138+ plasma cell formation were reported.
Specifically, hUC-MSC were shown to increase PAX-5 and decrease PRDM1 expression on
B cells [88], while CM-hAMSC strongly inhibited IRF-4, PRDM1, and XBP1 transcription,
consequently impairing B cell terminal differentiation [85].
Perinatal cells not only modulate B cell function by influencing their differentiation to-
ward plasma cells, but they also promote the formation of regulatory B cells (Bregs). Morandi
and colleagues reported that hAEC promoted the expansion of CD19+CD24hiCD38hi Bregs,
inferring an involvement of the immunosuppressive molecule adenosine [92]. Xue Qun
and colleagues, however, take the opposite view, suggesting that the immune modulation
performed in vitro by perinatal cells might not directly involve IL-10+ Bregs, whose formation
turns out to be inhibited by human amniotic fluid stromal cells [91].
Identification of the signaling pathways involved in B cell proliferation and differ-
entiation that are affected by perinatal cells could help to partially clarify the impact of
perinatal cells on B cells. We recently demonstrated the strong immunoregulation abil-
ity exerted by hAMSC on B cells activated in a T-independent manner through CpG
oligodeoxynucleotides (CpG ODN) stimulus [85]. We show that two different signaling
pathways activated downstream the CpG ODN stimulus: the Toll-like receptor 9 (TLR9)-
myeloid differentiation primary response 88 (MyD88)-interleukin-1 receptor-associated
kinase (IRAK)1/4 and TLR9-phosphatidylinositol 3-kinase (PI3K)-protein kinase B (AKT)
pathways [101–103] are suppressed by hAMSC, causing a reduction of the expression of
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the CpG ODN-uptake sensors CD205, TLR9, and CD14. As a consequence, we detected the
inhibition of IRAK-4 (intracellular signaling mediator) expression, followed by inhibition
of mitogen-activated protein kinases (MAPK) (c-Jun N-terminal Kinase (JNK), p38 MAPK,
extracellular signal-regulated kinase (ERK)) and nuclear factor kappa-light-chain-enhancer
of activated B cells (NF-kB) pathways and a significant decrease in the expression of
phosphorylated AKT [85]. Similar results have been described for hUC-MSC by Che N.
and colleagues, who reported the inhibition of AKT and p38 MAPK phosphorylation in
a dose-dependent manner in B cells activated in a T-dependent manner through B cell
receptor (BCR) activation [88].
The exact mechanism by which perinatal tissue-derived cells regulate the immune
response is still unknown, but a large body of evidence demonstrates that their restorative
effect is largely mediated by the secretion of active molecules [104]. In literature, many
soluble factors have been proposed as possible mediators of perinatal cell regulation of
B cells. Previous data have demonstrated that prostanoids, and in particular prostaglandin
E2 (PGE2), are partially involved in the mechanism through which perinatal cells exert their
immunomodulatory effect on immune cells [105–107]. Two recent studies, including ours,
have demonstrated that prostanoids may be partially involved in the immunomodulatory
actions of perinatal cells on B cells, but they showed a partially opposite effect. On one
hand, prostanoids secreted by hAMSC promote the inhibitory capacity of these cells on
proliferation and formation of antibody secreting cell but not on terminal maturation into
plasma cells [85]. On the other hand, PGE2, released by hUC-MSC, might cooperate with
other hUC-MSC-derived soluble cytokines to promote the proliferation and differentiation
of humoral immunity in vitro [94].
5.2. In Vivo
Due to their intriguing immunomodulatory properties, perinatal cells have shown
therapeutic effects in the treatment of inflammatory and immune-mediated diseases, such
as lung [108,109] and liver [110] fibrosis, inflammatory bowel disease [111], wound heal-
ing [107,112], collagen-induced arthritis [111], multiple sclerosis [111], traumatic brain
injury [113], experimental autoimmune encephalomyelitis [111], cerebral ischemia [114],
Huntington’s disease [115], and diabetes [116].
Very few studies explored and proved the therapeutic efficacy of perinatal cells in
pathological conditions driven by B cells (Figure 2 and Table 1).
Recently, our group provided key insights into the effect of hAMSC on B lymphocytes
in a mouse model of idiopathic pulmonary fibrosis (IPF), a lung disease driven by inflam-
mation and characterized by progression of fibrotic processes [86]. The pathogenesis of IPF
remains poorly understood, but the presence of lymphoid aggregates, containing either T
or B cells, in the lung tissue concurrent with autoantibodies to self-antigens in IPF patient
serum suggests a breakdown in central tolerance in adaptive immune cells [117]. Treat-
ment with hAMSC reduced fibrosis progression and better preserved alveolar integrity. In
parallel, hAMSC treatment maintained low levels of B cells in alveolar spaces and reduced
the amount of CD138+ antibody-secreting cells in lung tissues, suggesting a decrease in
B cell recruitment and an impairment of the maturation of B cells. Moreover, hAMSC coun-
teracted the formation and expansion of intrapulmonary lymphoid aggregates. The results
of this study pointed at a role for hAMSC in reducing the progression of fibrotic lesions by
modulating the lung expression of different homeostatic lymphoid chemokines, such as
chemokine (C-X-C motif) ligand 13 (CXCL13), and the expression of B-cell activating factor
(BAFF), involved in B cell survival and maturation [86].
In another study, allogenic transplantation of hAEC showed remarkable therapeutic
effects in animal models of autoimmune disorders, such as Hashimoto’s thyroiditis (HT)
and systemic lupus erythematosus (SLE) [118]. Despite being characterized by different
target organs and inflammatory processes, both of these diseases develop as a result of
the breakdown of the immune tolerance to self-antigens, characterized by presence of
autoantibodies produced by activated B cells and self-reactive T cells that act against self-
Int. J. Mol. Sci. 2021, 22, 3405 10 of 18
antigens, consequently resulting in tissue damage [119,120]. hAEC injection reduced the
severity of the disease, with organ function preservation, reduction of inflammation, and
restoration of immune-balance in experimental autoimmune thyroiditis (EAT) and SLE
mice. Focusing on B cell compartment, a selective and significant upregulation of Bregs
was reported in EAT mice upon hAEC treatment, laying out regulatory B cells that produce
IL-10 (B10) as the major target subset of hAEC. Nevertheless, hAEC had little effect on
the B10 population in SLE mice, where evidence of reduced autoantibody production was
reported. These distinct results suggest a different immune modulatory mechanism of
hAEC according to disease, probably related also to the distinct Bregs behavior in these
autoimmune disorders [118].
The effect of perinatal cells on the B cell compartment was also evaluated in a clinical
study in which hUC-MSC were infused as a strategy for chronic graft-versus-host disease
(cGVHD) prophylaxis in patients after human leukocyte antigen (HLA)-haploidentical
hematopoietic stem-cell transplantation (HLA-haplo HSCT) [121]. In recent years, in
fact, remarkable advances support the idea that, although the T cells remain the main
effectors, B cells may also play an important role in the pathogenesis of cGVHD. The
mechanisms by which B cells contribute to cGVHD are still incompletely understood, but
a marked perturbation of B cell homeostasis was detected in cGVHD patients [122]. In
particular, studies have shown that cGVHD patients exhibit a deficiency of memory B cell
subpopulation and that this B lymphocyte subset positively impacts long-term allograft
acceptance after renal transplantation [122,123]. The results of this clinical trial showed that
repeated infusion of hUC-MSC might minimize the severity and the symptoms of cGVHD.
Concurrently, changes in the numbers and subtypes of T, B, and NK cells were detected,
suggesting a possible improvement of immune tolerance. Concerning B cells, a relevant
increase of CD27+ memory B cells was observed after hUC-MSC injection, suggesting that
perinatal cell infusion most likely affected the memory B cell subpopulation.
Table 1. Effects of perinatal cells on B cells.





In vitro co-cultured with
purified mouse splenic
B cells stimulated by CpG+
IgM + CD40L + IL-4 in a
contact-independent setting
- Abrogation of B220+ B cell proliferation
- Blockage of the terminal differentiation into
CD138+ plasma cells
- Reduction in immunoglobulin secretion
- Increase of PAX-5 and
suppression of Blimp-1 mRNA
expression
- Inhibition of Akt and p38
MAPK phosphorylation
[88]
In vitro co-cultured with the
Burkitt’s lymphoma cell line,
even in the absence of
cell–cell contact
- Abrogation of lymphoma cells proliferation - Arrest of lymphoma cellsdivision in the S phase [89]
In vitro co-cultured with
autoreactive B lymphocytes
from peripheral blood of
immune thrombocytopenic
patients
- Abrogation of CD19+ B cell proliferation - Not investigated [90]
In vitro co-cultured with
human PBMC stimulated by
PHA
- Not inhibition of CD19+ B cell proliferation - Not investigated [93]
In vitro co-cultured with
human purified B cells
stimulated by CpG+ IgA +
IgG + IgM + CD40L + IL-2,
even in the absence of
cell–cell contact
- Stimulation of CD19+ B cell proliferation
- Increase of CD138+ cell terminal differentiation,
and immunoglobulin production
- Prostaglandin E2 [94]
Clinical trial of cGVHD
prophylaxis in patients after
HLA-haplo HSCT
- Increase of CD27+ memory B cells - Not investigated [121]
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Table 1. Cont.
Perinatal






In vitro co-cultured of
human PBMC and
purified B cells
stimulated by CpG with
conditioned medium
from hAMSC
- Suppression of CD19+ B cell proliferation
- Blockage of ASC/pre-plasma cells
CD27+CD38+ formation
- Blockage of the terminal differentiation into
CD138+ plasma cells
- Increase CD19+CD27+CD38− memory
B cells






- Reduction of CpG sensors
(CD205, TLR9, and CD14)
- Inhibition of IRAK-4, and
phosphorylated MAPK (JNK,
p38 MAPK, ERK), NF-kB,
and AKT






- Reduction of B220 B cells in alveolar spaces
- Reduction of CD138+ antibody-secreting
cells in lung tissues
- Down-modulation of







In vitro co-culture of
human purified B cells
stimulated by CpG+
Immunoglobulin +
CD40L +IL-2 + IL-4
- Inhibition of CD19+ B cell proliferation and
activation (CD80/CD86 expression)
- Reduction of the proportion of
CD19+CD20+CD27+ memory B cells
- Blockage of CD19+CD20−CD27+ plasma
cells
- Reduction in immunoglobulin secretion
- Inhibition of IL-10+ cells Breg formation
- Downregulation of the proportion of CD5+
B1 cells
- Inhibition of apoptosis of activated B cell
- Decrease in the percentage
of B cells in S phase cycle




- Decrease in the expression
of B7H4 and PD-L1 in







In vitro co-culture with




- Increase in B cell proliferation
- Diminished spontaneous apoptosis
- Expansion of CD19+CD24hiCD38hi Bregs




- Upregulation of IL-10+ Bregs - Not investigated [118]
Experimental mouse
model of systemic lupus
erythematosus
- Reduction of autoantibody production - Not investigated [118]
CpG, Unmethylated cytosine-guanine (CpG) motif-containing oligodeoxynucleotides
(ODNs); CD40L, CD40 ligand; PAX-5, paired box 5; BLIMP-1, B lymphocyte induced
maturation protein-1; AKT, protein Kinase B; MAPK, mitogen-activated protein kinases;
HLA-haplo HSCT, Human Leukocyte Antigen-haploidentical hematopoietic stem-cell
transplantation; IRF-4, interferon regulatory factor 4; PRDM1, PR/SET domain 1; XBP-1,
X-box binding protein 1; TLR9-MyD88-IRAK1/4, Toll-like receptor 9 (TLR9)-myeloid differ-
entiation primary response 88 (MyD88)-interleukin-1 receptor-associated kinase (IRAK)1/4;
TLR9-PI3K-AKT, TLR9-phosphatidylinositol 3-kinase (PI3K)-protein kinase B (AKT); ERK,
extracellular signal-regulated kinase; JNK, c-Jun N-terminal Kinase; NF-kB nuclear factor
kappa-light-chain-enhancer of activated B cells; PBMC, peripheral blood mononuclear
cells; PHA, phytohemagglutinin; cGVHD, chronic graft-versus-host disease.
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6. Conclusions
While considering the very complex pathogenesis of PE, a growing body of evidence
suggests an important role of the altered immune system in the development of this disor-
der. In particular, B cells represent a dominant component of PE, leading to consideration
of PE as an autoimmune-like disease affecting the maternal–fetal interface, especially
due to the presence of circulating autoantibodies in PE patients [68,69]. It is known that
B cells play an important role in autoimmune and immune-mediated diseases, both as
pro-inflammatory cells, functioning either as antigen-presenting cells and immunoglobulin-
secreting cells, and regulatory cells, producing cytokines that control T cell, macrophage,
and natural killer cell functions.
Thus, the possibility of modulating B cell activation and function by exploiting peri-
natal immunomodulatory properties, could be a novel therapeutic tool, overcoming the
limitations of current treatments for PE [53]. As a matter of fact, ongoing therapeutic
approaches for B cell-mediated diseases are mainly based on global B cell depletion (with a
strong impact on general immune response), while perinatal cell administration could be a
strategy for a more refined modulation of B cell activity, focused on maintaining normal
B cell function and eliminating pathogenic B cells, which could prove more beneficial
for patients.
Several studies described the capacity of perinatal cells to impact on B cell response
at different levels: by inhibiting B cell proliferation, impairing B cell differentiation, and
promoting B regulatory cell formation. It could be of great interest to understand whether
the activities exerted by perinatal cells on B cells are guided by the surrounding pathologi-
cal/inflammatory microenvironment and are therefore dependent on the specific context.
However, although there is evidence of the ability of gestational tissue-derived cells to
favorably interact with B cells, some studies, in contrast, have reported pro-inflammatory
effects of perinatal cells on B cells. These conflicting results could be due to their application
of different experimental setups, such as using variable co-culture systems, stimulating
conditions, B cell lines, and perinatal cells from diverse sources.
In conclusion, after reviewing the literature, it is clear that perinatal cells hold the
potential of being a novel therapeutic approach for PE. However, the contradictory results
and the mainly small number of studies exploring the effect of perinatal cells on B cell
compartment cannot allow one to draw an unequivocal conclusion. Further in vitro and
in vivo studies are necessary to better elucidate the immunomodulatory capacity of perina-
tal cells as a viable strategy for the treatment of preeclampsia. Specifically, comparative
studies using perinatal cells derived from different compartments of the placenta and fetal
annexes could be of interest for understanding which cells better affect B cells. Moreover,
while there is the evidence of the effect of perinatal cells on B cells from healthy donors, the
investigation of B cells from PE pregnancy needs to be addressed, as well as the evaluation
of the efficacy of perinatal cells in animal models of PE.
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ROS Reactive Oxygen Species
sFlt-1 soluble Fms-like tyrosine kinase-1
VEGF Vascular-Endothelial Growth Factor
PlGF Placental Growth Factor
sEng Soluble Endoglin







Tregs Regulatory T cells
TNF Tumor Necrosis Factor
IFN Interferon
MPO Myeloperoxidase
hUC-MSC Human Umbilical Cord Mesenchymal Stromal Cells
PBMC Peripheral Blood Mononuclear Cells
hAMSC Human Amniotic Mesenchymal Stromal Sells
CM Conditioned Medium
B7H4 B7 homolog 4
PD-L1 Programmed Death-Ligand 1
hAEC Human Amniotic Epithelial Cells
ASC Antibody-Secreting Cells
PAX-5 Paired Box 5
BCL-6 B-cell CLL/Lymphoma 6
IRF4 Interferon Regulatory Factor 4
PRDM1 PR/SET Domain 1
BLIMP-1 B Lymphocyte Induced Maturation Protein-1
XBP-1 X-box Binding Protein 1
CpG ODN CpG Oligodeoxynucleotides
TLR9 Toll-Like Receptor 9
MyD88 Myeloid Differentiation Primary Response 88
IRAK1 Interleukin-1 Receptor-Associated Kinase 1
IRAK4 Interleukin-1 Receptor-Associated Kinase 4
PI3K Phosphatidylinositol 3-Kinase
AKT Protein Kinase B
MAPK Mitogen-Activated Protein Kinases
JNK c-Jun N-terminal Kinase
p38 MAPK p38 Mitogen-Activated Protein Kinases
ERK Extracellular Signal-Regulated Kinase
NF-kB Nuclear Factor Kappa-Light-Chain-Enhancer Of Activated B cells
BCR B cell Receptor
PGE2 Prostaglandin E2
IPF Idiopathic Pulmonary Fibrosis
CXCL13 Chemokine (C-X-C motif) Ligand 13
BAFF B-Cell Activating Factor
HT Hashimoto’s Thyroiditis
SLE Systemic Lupus Erythematosus
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Bregs Regulatory B cells
B10 Regulatory B cells that produce IL-10
cGVHD Chronic Graft-Versus-Host Disease
HLA Human Leukocyte Antigen
HLA-haplo HSCT HLA-Haploidentical Hematopoietic Stem-Cell Transplantation
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